VFA
LSTA icon

Virtus Fund Advisers’s Lisata Therapeutics LSTA Stock Holding History

Virtus Fund Advisers’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-13
Closed -$13K – 1574
2014
Q2 		$13K Buy
+13
New +$12.6K ﹤0.01% 2671

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Virtus Fund Advisers's LSTA Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Lisata Therapeutics (LSTA) in Q3 2014, closing a stake of 13 shares — an estimated $13K sold.

Virtus Fund Advisers first reported a position in LSTA in Q2 2014 and held it in 1 quarter. The position peaked at $13K in Q2 2014. 50 funds tracked by Wall St. Rank hold LSTA as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Lisata Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 13 Lisata Therapeutics shares in Q3 2014, an estimated $13K.
  • Virtus Fund Advisers first reported a position in Lisata Therapeutics in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Lisata Therapeutics position peaked at $13K in Q2 2014.
  • 50 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.